Multicenter/Fetal Myelomeningocele Repair-Supplement

多中心/胎儿脊髓脊膜膨出修复补充剂

• 批准号: 6827182
• 负责人: Edmund Y Yang
• 金额: $ 15.67万
• 依托单位: VANDERBILT UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2001
• 资助国家: 美国
• 起止时间: 2001-06-01 至 2007-02-28
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6827182
• 关键词: Multicenter; Fetal; Myelomeningocele; Repair; Supplement

DESCRIPTION (provided by applicant): The Management of Myelomeningocele Study (MOMS) is a multi-center unblinded randomized clinical trial of 200 patients that is underway at three clinical centers, the University of California-San Francisco, The Children's Hospital of Philadelphia, and Vanderbilt University Medical Center, and a data coordinating center. The primary objective of the trial is to determine whether intrauterine repair of fetal myelomeningocele at 19o to 256 weeks gestation improves outcome, as measured by 1) death or the need for ventricular decompressive shunting by one year of life, and 2) a composite neurologic function score at 30 months corrected age. Only a small percentage of children with spina bifida are born with a normal innervation of their bladder and sphincter muscles, with urologic sequelae that are life-long. The effect of prenatal surgery for myelomeningocele on subsequent urologic function is unknown, but vitally important to determine. This proposal is for a supplement to the MOMS trial to initiate a more rigorous urologic follow-up of the infants in the trial. It is anticipated that 120 infants will receive renal sonography, video urodynamics and urinalysis, culture and sensitivity at three time points during the study: before neonatal discharge following delivery, at 12 months, and 30 months corrected age. The aim of the supplement is to determine whether in utero treatment of open myelomeningocele affects the outcome with respect to urinary tract infection, and the need for intermittent catheterization. A committee of three independent pediatric urologists will review medical records and imaging studies to determine whether infants meet objective criteria for clean intermittent catheterization.

描述（由申请人提供）：脊髓脊膜膨出管理研究（MOMS）是一项在三个临床中心（加利福尼亚大学-旧金山弗朗西斯科分校、费城儿童医院和范德比尔特大学医学中心）和一个数据协调中心进行的200例患者的多中心非盲随机临床试验。该试验的主要目的是确定在妊娠19 o至256周时对胎儿脊髓脊膜膨出进行宫内修复是否能改善结局，通过1）死亡或1岁时需要心室减压分流术，以及2）30个月矫正年龄时的复合神经功能评分进行测量。 只有一小部分脊柱裂患儿出生时膀胱和括约肌的神经支配正常，泌尿系统后遗症是终身的。产前手术治疗脊髓脊膜膨出对随后泌尿系统功能的影响尚不清楚，但确定这一点至关重要。 该提案是对MOMS试验的补充，旨在对试验中的婴儿进行更严格的泌尿科随访。预计120名婴儿将在研究期间的三个时间点接受肾超声检查、视频尿动力学和尿分析、培养和敏感性检查：分娩后新生儿出院前、12个月和30个月矫正年龄。该补充的目的是确定开放性脊髓脊膜膨出的宫内治疗是否影响尿路感染的结局，以及是否需要间歇性导尿。一个由三名独立的儿科泌尿科医生组成的委员会将审查医疗记录和成像研究，以确定婴儿是否符合清洁间歇导尿的客观标准。